Welcome to a MedTech West seminar: The use of positron emission tomography (PET) in the early detection of Alzheimer’s disease
Cumulated scientific evidence suggests that the pathology causing Alzheimer’s disease (AD) occurs many years or even decades before memory impairment and other clinical symptoms arise. Tangible and detailed knowledge about different pathological processes, their interactions, and time course is therefore of the essence both for the development of potentially successful treatments and a reliable early diagnosis of this relentless disorder.
The past decade has seen an explosion in research on biomarkers that could provide in vivo evidence for these pathological processes.
The rare form of dominantly inherited early-onset familial AD (eoFAD), with almost complete mutation penetrance and defined age of disease onset, has been proposed as a model to study the earliest disease mechanisms that are also supposed to underlie the common sporadic form of AD (sAD). We used positron emission tomography (PET), a powerful nuclear medical imaging technique that can produce three-dimensional functional maps of processes in the brain, to explore the characteristics, time course and interrelationship of relevant biomarkers at presymptomatic and symptomatic disease stages of AD.
The seminar will be presented by Michael Schöll, a new addition to the MedTech West team.
Date: December 3
Time: 11:30-12:15 (-13 incl lunch)
Room: Hjärtats aula, Vita Stråket 12, Sahlgrenska Universitety Hospital
Register by sending an email to email@example.com. Please write “Seminar December 3” in the subject line. Last day for registration is November 28.